Zenas BioPharma logo

Zenas BioPharma

ZBIO | NASDAQ
Chart Builder DCF Calculator
$27.93
-$0.08 (-0.29%)
At close: Nov 16, 2026, 4:00 PM ET
$27.93
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.29%

Rating

Updated: Nov 16, 2026
38.5
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #569/1021 (Top 56%)

Key Statistics

Market Data

Market Cap $1.89B
1D Range
27.50 28.21
52W Range
15.20 43.17

Valuation (TTM)

PE -2.78
PB 8.92
EV/EBITDA -3.05

Valuation (NTM)

Forward PE N/A
Forward PEG -0.06
Price Target $43.50
Loading financial charts...

Profile

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary inve...

Sector Healthcare
Industry Biotechnology
Employees 167
IPO Date Sep 13, 2024
Fiscal Year January - December

Latest News

Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears

18 days ago · marketbeat.com

Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision Nears
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript

21 days ago · seekingalpha.com

Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know

25 days ago · zacks.com

Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know
Zenas BioPharma to Host Virtual R&D Event

1 month ago · globenewswire.com

Zenas BioPharma to Host Virtual R&D Event
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

1 month ago · seekingalpha.com

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript

2 months ago · seekingalpha.com

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

2 months ago · seekingalpha.com

Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

2 months ago · globenewswire.com

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

2 months ago · globenewswire.com

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$1.65
Miss -33.06%
REV
$10M
Miss -28.95%
Next Earnings
Mar 15, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$43.50
Upside
+55.75%
Buy (4)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.